ClinicalTrials.gg
Not yet recruitingNCT06924736Updated Apr 11, 2025

SONICURE(SONICracker for the Treatment of UndeRExpansion)

An interventional study of Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter and Non - compliant balloon dilatation catheter in Coronary Artery Disease, sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-04-11.

Sponsored by Shanghai Bluesail Boyuan Medical Technology Co., Ltd. (part of Blue Sail Medical Co., Ltd.) · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. — 8 open to participants now, 11 under way, none of them phase 3. Coronary Artery Disease · Blue Sail Medical Co., Ltd..

Planned enrollment
7th of 16
200 · median 200
Started
2025
with 1 other
No phase
16 of 23
7 open now
Primary completion
2026-06
later than 8 of 10 live
Registered
21st of 23
by date

Among the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., this one is the 7th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 16 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 21st registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Coronary Artery Disease by Blue Sail Medical Co., Ltd., or all of them as a file.
02

Study summary

The first-phase study is a prospective, single-group observational study. It plans to recruit patients with in-stent restenosis caused by poor stent expansion in the coronary artery. The intravascular shock wave treatment device and the disposable coronary intravascular shock wave catheter produced by Shanghai Lifan Boyuan Medical Technology Co., Ltd. will be used for treatment. This is a clinical trial to verify the feasibility, preliminary safety and effectiveness of treating in-stent restenosis caused by poor stent expansion in the coronary artery.

The second-phase study is a prospective, multicenter, randomized controlled clinical trial is planned to recruit patients with in - stent restenosis caused by poor coronary stent expansion. These patients will be treated with either the intravascular shock wave treatment device and the disposable coronary intravascular shock wave catheter produced by Shanghai Lifan Boyuan Medical Technology Co., Ltd., or a non - compliant balloon dilation catheter (Shandong JW Medical Products Co., Ltd., National Medical Device Registration No. 20213031019). The purpose is to verify the safety and effectiveness of the investigational medical devices in treating in - stent restenosis caused by poor coronary stent expansion.

Read the detailed description

In the first phase, it will be carried out at Beijing Luhe Hospital, Capital Medical University. A total of 10 subjects are planned to be enrolled. After the subjects are included in the study, they will be treated with the intravascular shock wave treatment device and the disposable coronary intravascular shock wave catheter produced by Shanghai Lifan Boyuan Medical Technology Co., Ltd. Clinical follow-ups will be conducted before discharge and one month after the operation.

In the second phase, it will be carried out at multiple clinical trial institutions in China. A total of 200 subjects are planned to be enrolled. After randomization, all subjects will undergo surgical treatment using either the investigational device or the control device. Clinical follow - up will be conducted before discharge, 1 month after surgery, and 6 months after surgery.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • SONICURE
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 80 years old, either male or non - pregnant female.
  • Suffering from heart diseases with clinical evidence of ischemia, such as Chronic Coronary Syndrome (CCS) or Acute Coronary Syndrome (ACS).
  • The subject should be able to understand the purpose of the trial, voluntarily participate in it, and sign the form.
  • During the baseline surgery, at most one target lesion can be treated.
  • The target lesion and non - target lesion are not located in the same blood vessel.
  • The reference vessel diameter of the target lesion is 2.25 - 4.0 mm (estimated visually).

Exclusion criteria

Exclusion Criteria:

  • Patients who have had any myocardial infarction within 1 week, or patients who have had a myocardial infarction more than 1 week ago but whose myocardial enzymes CK or CK-MB have not yet returned to normal.
  • Patients with (NYHA) class III or IV heart failure or those with severe valvular heart disease.
  • Female patients who are planning to become pregnant (or are breastfeeding).
  • Severe impairment of liver and kidney function, with transaminase levels more than 3 times the value, serum creatinine > 2.5 mg/dL (221 μmol/L), or chronic renal failure requiring long-term dialysis.
  • Severe hypertension that cannot be controlled despite treatment (systolic blood pressure persistently > 180 mmHg or diastolic blood pressure persistently > 110 mmHg).
  • Coagulation disorders, with a count \< 100×10⁹/L.
  • Patients with cardiogenic shock.
  • Patients who need to receive cytostatic agents or radiotherapy due to accompanying diseases.
  • Patients known to be allergic to heparin, contrast agents, aspirin, clopidogrel, or anesthetics.
  • Patients with a bleeding diathesis, or those with a history of cerebral hemorrhage, active peptic ulcer, or gastrointestinal bleeding within the past 6 months, for whom anticoagulant therapy or the use of anticoagulant drugs will be restricted or prohibited.
  • Patients with a of less than 6 months or those with potential factors that may cause difficulties in clinical follow-up.
  • Patients who are currently participating in any other clinical trial. Patients who, for other reasons, are considered by the investigator to be unsuitable for inclusion.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter

    Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter (Shanghai Lanfan Boyuan Medical Technology Co., Ltd.)

    Device: Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter

  • Active comparator
    non-compliant balloon dilatation catheter

    Randomized to the control group using a non-compliant balloon dilatation catheter (Shandong Jiwei Medical Products Co., Ltd.) to treat the lesion

    Device: Non - compliant balloon dilatation catheter

Interventions

  • DeviceIntravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter

    Randomly assign subjects to the experimental group to treat the lesions with an intravascular shockwave therapy device/disposable coronary artery shockwave catheter.

  • DeviceNon - compliant balloon dilatation catheter

    Randomly assign subjects to the control group to treat the lesions with a non - compliant balloon catheter.

06

What researchers measure

Primary outcomes

  1. Surgical success rate

    The residual stenosis after the operation is ≤ 30%, and there is no occurrence of Major Adverse Cardiac Events (MACE) during the hospitalization period (up to 7 days after the operation).

    Time frame: during the hospitalization period (up to 7 days after the operation).

Secondary outcomes

  1. Device success rate

    Security endpoint

    Time frame: Immediately after the operation

  2. The minimum stent area immediately after the operation(MSA)

    Measured by Optical Coherence Tomography (OCT)

    Time frame: Immediately after the operation

  3. The minimum stent lumen diameter immediately after the operation(MLD)

    Measured by Optical Coherence Tomography (OCT)

    Time frame: Immediately after the operation

  4. The incidence of Major Adverse Cardiovascular Events (MACE)

    Safety endpoint

    Time frame: before discharge, one month after the operation

  5. The incidence of target lesion failure (TLF)

    Safety endpoint

    Time frame: one month after the operation

  6. The incidence of serious adverse events

    Safety endpoint

    Time frame: before discharge, one month after the operation

  7. The incidence of device defects

    Safety endpoint

    Time frame: during the operation

  8. The incidence of serious angiographic complications

    Safety endpoint

    Time frame: during the operation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Jun 2026, 12 months later.

Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's planned 12 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Apr 11, 2025
StartEst.
May 15, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06924736
Responsible party
Sponsor
First posted
Apr 11, 2025
Start date
May 15, 2025 (estimated)
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 11, 2025

Study contacts

Yang Wang
Contact
yang.wang@jwmsgrp.com
13366024088
Yuanchun Sun
Contact
13683382436
Guangyao Zhai
principal investigator · Beijing Luhe Hospital Affiliated to Capital Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion